• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    XOMA Royalty Announces Closing of Tender Offer for Turnstone Biologics

    8/11/25 9:00:00 AM ET
    $TSBX
    $XOMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TSBX alert in real time by email

    - Turnstone Stockholders Received $0.34 Per Share in Cash Plus Contingent Value Right -

    EMERYVILLE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA) ("XOMA Royalty" or the "Company"), a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health, today announced the Company has successfully completed its previously announced tender offer to acquire all outstanding shares of Turnstone Biologics Corp. (NASDAQ:TSBX) common stock for a price per share of $0.34 in cash (the "Cash Amount"), plus one non-tradeable contingent value right ("CVR" and together with the Cash Amount, the "Offer Price").

    The tender offer and related withdrawal rights expired one minute after 11:59 p.m. Eastern Time on Thursday, August 7, 2025 (the "Expiration Date").  As of the Expiration Date, a total of 17,192,002 shares of Turnstone common stock were validly tendered, and not validly withdrawn, representing approximately 74% of the outstanding shares of Turnstone common stock as of the Expiration Date.  As of the Expiration Date, the number of shares validly tendered in accordance with the terms of the tender offer and not validly withdrawn satisfied the minimum tender condition, and all other conditions to the tender offer were satisfied or waived.  Immediately after the Expiration Date, XOMA Royalty irrevocably accepted for payment all shares validly tendered and not validly withdrawn and expects to promptly pay for such shares.

    Following the closing of the tender offer, XOMA Royalty merged Turnstone with and into a subsidiary, XRA 3 Corp. (the "Merger"), and all shares of Turnstone common stock that had not been validly tendered were converted into the right to receive the Offer Price.  As a result of the Merger, Turnstone became a wholly owned subsidiary of XOMA Royalty.  Prior to the opening of trading on The Nasdaq Stock Market LLC ("Nasdaq") on August 11, 2025, all shares of Turnstone common stock will cease trading on Nasdaq, and Turnstone intends promptly to cause such shares to be delisted from Nasdaq and deregistered under the Securities Exchange Act of 1934, as amended.

    Advisors

    XOMA Royalty was represented by Gibson, Dunn & Crutcher LLP.  Leerink Partners acted as the exclusive financial advisor and Cooley LLP acted as legal counsel to Turnstone.

    About XOMA Royalty Corporation

    XOMA Royalty is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health.  XOMA Royalty acquires the potential future economics associated with pre-commercial and commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies.  When XOMA Royalty acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes.  XOMA Royalty has an extensive and growing portfolio of assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate).  For more information about XOMA Royalty and its portfolio, please visit www.xoma.com or follow XOMA Royalty Corporation on LinkedIn.

    Forward-Looking Statements/Explanatory Notes

    Certain statements contained in this press release are forward-looking statements, including statements regarding the payment and timing of payment of the Offer Price to former Turnstone common stockholders and the ability and timing of delisting of Turnstone's common stock.  In some cases, you can identify such forward-looking statements by terminology such as "expect," "may," or "will," the negative of these terms or similar expressions.  These forward-looking statements are not a guarantee of XOMA Royalty's performance, and you should not place undue reliance on such statements.  These statements are based on assumptions that may not prove accurate, and actual results could differ materially from those anticipated due to certain risks including that XOMA Royalty does not achieve anticipated net cash after winding down Turnstone's operations, that the timing of the payment or delisting may be delayed and that there are no payments made under the CVRs.  Other potential risks to XOMA Royalty meeting these expectations are described in more detail in XOMA Royalty's most recent filing on Form 10-Q and in other filings with the Securities and Exchange Commission ("SEC").  Any forward-looking statement in this press release represents XOMA Royalty's beliefs and assumptions only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date.  XOMA Royalty disclaims any obligation to update any forward-looking statement, except as required by applicable law.

    EXPLANATORY NOTE: Any references to "portfolio" in this press release refer strictly to milestone and/or royalty rights associated with a basket of drug products in development.  Any references to "assets" in this press release refer strictly to milestone and/or royalty rights associated with individual drug products in development.



    XOMA Royalty Investor Contact XOMA Royalty Media Contact
    Juliane Snowden

    XOMA Royalty Corporation

    +1 646-438-9754

    [email protected]

    Kathy Vincent

    KV Consulting & Management

    [email protected]


    Primary Logo

    Get the next $TSBX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TSBX
    $XOMA

    CompanyDatePrice TargetRatingAnalyst
    XOMA Royalty Corporation
    $XOMA
    4/17/2025$35.00Buy
    The Benchmark Company
    Turnstone Biologics Corp.
    $TSBX
    2/5/2025$3.75 → $0.40Overweight → Neutral
    Piper Sandler
    Turnstone Biologics Corp.
    $TSBX
    11/15/2024Neutral → Underperform
    BofA Securities
    Turnstone Biologics Corp.
    $TSBX
    10/14/2024Buy → Neutral
    BofA Securities
    XOMA Royalty Corporation
    $XOMA
    4/29/2024$40.00Outperform
    Leerink Partners
    Turnstone Biologics Corp.
    $TSBX
    8/16/2023Market Perform
    SVB Securities
    Turnstone Biologics Corp.
    $TSBX
    8/15/2023$20.00Overweight
    Piper Sandler
    Turnstone Biologics Corp.
    $TSBX
    8/15/2023$18.00Buy
    BofA Securities
    More analyst ratings

    $TSBX
    $XOMA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    The Benchmark Company initiated coverage on XOMA Royalty Corporation with a new price target

    The Benchmark Company initiated coverage of XOMA Royalty Corporation with a rating of Buy and set a new price target of $35.00

    4/17/25 8:34:06 AM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Turnstone Biologics downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Turnstone Biologics from Overweight to Neutral and set a new price target of $0.40 from $3.75 previously

    2/5/25 8:04:09 AM ET
    $TSBX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Turnstone Biologics downgraded by BofA Securities

    BofA Securities downgraded Turnstone Biologics from Neutral to Underperform

    11/15/24 8:23:44 AM ET
    $TSBX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TSBX
    $XOMA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ESSA Pharma Inc. Amends Agreement with XenoTherapeutics

    Shareholders expected to receive approximately $0.12 per share in cash upon closing of transaction and up to approximately $0.14 per CVR under revised terms Further Adjourns Special Meeting to October 3, 2025 SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, Sept. 24, 2025 /PRNewswire/ -- ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ:EPIX) today announced that it has reached an agreement to amend its previously announced Business Combination Agreement (the "Amended Agreement") with XenoTherapeutics Inc. ("Xeno"), a non-profit biotechnology company. XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA) continues to act as structuring agent and intends to provide financing for the transac

    9/24/25 6:00:00 AM ET
    $EPIX
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mural Oncology Announces Commencement of Mailing of Definitive Proxy Statement and Details of Scheme Meeting and Extraordinary General Meeting

    WALTHAM, Mass. and DUBLIN, Ireland, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc, (NASDAQ:MURA) ("Mural"), a clinical-stage immuno-oncology company, today announces for the purposes of the Irish Takeover Panel Act, 1997, Takeover Rules 2022 (the "Irish Takeover Rules"), that it has published the definitive proxy statement of Mural relating to the Acquisition described below, which also constitutes a scheme circular under Irish law (the "Proxy Statement") and that Mural has commenced mailing the Proxy Statement to Mural shareholders. As previously announced on August 20, 2025, XOMA Royalty Corporation (NASDAQ:XOMA) ("XOMA Royalty") and Mural entered into a definitive transaction

    9/23/25 7:52:56 PM ET
    $MURA
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    XOMA Royalty Declares Quarterly Preferred Stock Dividends

    EMERYVILLE, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA Royalty's Series A and Series B Cumulative Preferred Stock:   Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (NASDAQ:XOMAP) shall receive a cash dividend equal to $0.53906 per share.   Holders of depositary shares, each representing 1/1000 of a share of XOMA Royalty's 8.375% Series B Cumulative Perpetual Preferred Stock (NASDAQ:XOMAO), shall receive a cash dividend equal to $0.52344 per depositary share.   The preferred dividends will be paid on or about October 15, 2025, t

    9/22/25 7:30:00 AM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TSBX
    $XOMA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Investment Officer Sitko Bradley bought $50,780 worth of Depositary Shares - 8.375% Series B Cumulative Stock (2,000 units at $25.39), increasing direct ownership by 40% to 7,045 units (SEC Form 4)

    4 - XOMA Royalty Corp (0000791908) (Issuer)

    7/2/25 4:30:26 PM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Investment Officer Sitko Bradley bought $49,400 worth of Depositary Shares - 8.375% Series B Cumulative Stock (2,000 units at $24.70), increasing direct ownership by 66% to 5,045 units (SEC Form 4)

    4 - XOMA Royalty Corp (0000791908) (Issuer)

    4/9/25 4:44:30 PM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Limber Joseph M bought $504,504 worth of Depositary Shares - 8.375% Series B Cumulative Stock (20,000 units at $25.23) and bought $255,640 worth of 8.625% Series A Cumulative Perpetual Preferred Stock (10,000 units at $25.56) (SEC Form 4)

    4 - XOMA Royalty Corp (0000791908) (Issuer)

    4/7/25 4:39:59 PM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TSBX
    $XOMA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Investment Officer Sitko Bradley converted options into 6,712 shares, increasing direct ownership by 51% to 19,822 units (SEC Form 4)

    4 - XOMA Royalty Corp (0000791908) (Issuer)

    9/23/25 5:32:53 PM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Hughes Owen converted options into 35,567 shares, increasing direct ownership by 57% to 98,268 units (SEC Form 4)

    4 - XOMA Royalty Corp (0000791908) (Issuer)

    9/23/25 5:32:38 PM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP, Finance & CFO Burns Thomas M. sold $155,820 worth of shares (4,330 units at $35.99) and converted options into 11,846 shares, increasing direct ownership by 33% to 30,079 units (SEC Form 4)

    4 - XOMA Royalty Corp (0000791908) (Issuer)

    9/23/25 5:32:22 PM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TSBX
    $XOMA
    SEC Filings

    View All

    SEC Form 8-K filed by XOMA Royalty Corporation

    8-K - XOMA Royalty Corp (0000791908) (Filer)

    9/26/25 5:29:26 PM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    XOMA Royalty Corporation filed SEC Form 8-K: Financial Statements and Exhibits

    8-K - XOMA Royalty Corp (0000791908) (Filer)

    9/23/25 5:13:38 PM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 15-12G filed by Turnstone Biologics Corp.

    15-12G - Turnstone Biologics Corp. (0001764974) (Filer)

    8/21/25 9:00:49 AM ET
    $TSBX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TSBX
    $XOMA
    Leadership Updates

    Live Leadership Updates

    View All

    Turnstone Biologics Corp. Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights

    SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today reported financial results for the first quarter ended March 31, 2024, and provided recent business highlights. "We are excited about the therapeutic potential of our pipeline of next-generation Selected TIL therapies," said Sammy Farah, M.B.A., Ph.D., Turnstone's President and Chief Executive Officer. "The next frontier for TIL therapy is to extend its therapeutic activity

    5/13/24 5:01:26 PM ET
    $TSBX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities

    Earned $9 million milestone upon U.S. Food and Drug Administration's approval of Day One's OJEMDA™ (tovorafenib); XOMA is entitled to receive a mid-single digit royalty on OJEMDA™ sales Acquired Kinnate Pharmaceuticals, adding at least $9.5 million in non-dilutive capital to XOMA's balance sheet Expanded the commercial royalty and milestone portfolio with the acquisitions of economic interests in DSUVIA® (sufentanil sublingual tablet) and XACIATO™ (clindamycin phosphate) vaginal gel 2%, as well as two Phase 3 assets Launched XOMA's first stock repurchase program for up to $50 million EMERYVILLE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA), the biotech royal

    5/9/24 7:30:00 AM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Actym Therapeutics Appoints Thomas Smart as CEO

    BERKELEY, Calif., April 24, 2024 /PRNewswire/ -- Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today the appointment of Thomas Smart as Chief Executive Officer. With 25 years of experience in senior management and executive roles as well as Board of Directors positions across the biopharmaceutical industry, Mr. Smart brings a significant track record in leading organizations through value-building transitions. His breadth of expertise will be highly beneficial to Actym as it prepares to enter clinical evaluation of its lead candidate, ACTM-838, later this year.

    4/24/24 9:00:00 AM ET
    $ANAB
    $PGEN
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TSBX
    $XOMA
    Financials

    Live finance-specific insights

    View All

    XOMA Royalty Declares Quarterly Preferred Stock Dividends

    EMERYVILLE, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA Royalty's Series A and Series B Cumulative Preferred Stock:   Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (NASDAQ:XOMAP) shall receive a cash dividend equal to $0.53906 per share.   Holders of depositary shares, each representing 1/1000 of a share of XOMA Royalty's 8.375% Series B Cumulative Perpetual Preferred Stock (NASDAQ:XOMAO), shall receive a cash dividend equal to $0.52344 per depositary share.   The preferred dividends will be paid on or about October 15, 2025, t

    9/22/25 7:30:00 AM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share

    WALTHAM, Mass., DUBLIN, Ireland and EMERYVILLE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA), a clinical-stage immuno-oncology company ("Mural"), and XOMA Royalty Corporation (NASDAQ:XOMA), a biotechnology royalty aggregator ("XOMA Royalty"), announced today they have entered into a definitive agreement pursuant to which XRA 5 Corp., a newly formed company wholly owned by XOMA Royalty ("Sub"), has agreed to acquire the entire issued and to be issued share capital of Mural for cash (the "Acquisition") subject to the satisfaction of the closing conditions set out in Appendix I of this Announcement (the "Conditions"), including approval by Mural Shareholders. Fol

    8/20/25 8:30:00 AM ET
    $MURA
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right

    EMERYVILLE, Calif. and UTRECHT, The Netherlands and PHILADELPHIA, Aug. 04, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA) and LAVA Therapeutics N.V. ("LAVA") (NASDAQ:LVTX) announced today they have entered a definitive share purchase agreement (the "Purchase Agreement" and the transactions set forth in the Purchase Agreement, the "Transactions") whereby XOMA Royalty will acquire LAVA for (i) between $1.16 and $1.24 per share in cash, consisting of (A) USD $1.16 (the "Base Price Per Share") in cash per share (the "LAVA common stock"), plus (B) an additional amount of cash of up to $0.08 per Share (such amount as finally determined in accordance with the Pur

    8/4/25 7:30:00 AM ET
    $LVTX
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TSBX
    $XOMA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Turnstone Biologics Corp. (Amendment)

    SC 13G/A - Turnstone Biologics Corp. (0001764974) (Subject)

    5/31/24 4:23:52 PM ET
    $TSBX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Turnstone Biologics Corp. (Amendment)

    SC 13G/A - Turnstone Biologics Corp. (0001764974) (Subject)

    4/29/24 8:22:22 AM ET
    $TSBX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Turnstone Biologics Corp.

    SC 13G - Turnstone Biologics Corp. (0001764974) (Subject)

    3/18/24 9:13:28 PM ET
    $TSBX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care